登录

Cygnus Biosciences Raises ¥100M in Series C, Developing Gene Sequencing Machines

作者: Mailman 2020-06-15 08:59
赛纳生物
http://www.cygnusbio.com/
企业数据由 动脉橙 提供支持
国产高通量基因测序仪平台生产商 | C+轮 | 运营中
中国-北京
2023-03-20
融资金额:数亿人民币
源码资本
查看

According to Yiou.com, on June 11, 2020, Cygnus Biosciences (Beijing) Co., Ltd. ("Cygnus Biosciences"), a biotechnology company focused on R&D of gene sequencing machines, has raised hundreds of millions in Series C round, led by Guangzhou High-tech Zone Science and Technology Holdings Group, a financial platform of GDD Financial Holdings Group, with participation from Jinhe Capital. 


At the same time, Cygnus Biosciences announced the cooperation with Guangzhou Development Zone that its technology achievements in gene sequencing will be launched in Guangzhou High-tech Zone.


Proceeds from the latest round will be used to build an industrial base, an R&D center and a sales headquarter in Guangzhou Development Zone, said Wu Lei, the co-founder and CEO of Cygnus Biosciences.


Founded in 2015, the core team of Cygnus Biosciences is led by the international famous scientist Xie Xiaoliang and CEO Wu Lei. The team includes Peking University Professor Huang Yanyi, who once served as the chief scientist for the development of the sequencing instrument for the National 863 Program, CTO Dr. Chen Zitian; Chemist Dr. Duan Haifeng, and Dr. Luo Kaiqin, a well-known Chinese scientist in the gene-sequencing field who has just joined the team.


Cygnus Biosciences is committed to developing innovative gene sequencing machines based on fluorogenic sequencing and error correction coding (ECC) technology, aiming to improve the NGS sequencing technology for lower cost and higher accuracy.


Based on the principle of NGS sequencing and the concept of "code check" in the field of information and communication, Cygnus Biosciences has created a high-precision sequencing method. After the completion of the sequencing, it uses the error-correcting decoding algorithm with high accuracy, to automatically detected trace sequencing errors in the process of sequencing and correct them, thus improving the accuracy with a certain length of reads.


This method can greatly reduce the application cost of sequencing of the same sample, and the error rate to one over ten thousand at the same time, which is on a par with the first generation sequencer and fits better in line with the high-standard sequencing demands of the clinical testing market.


>>>>

About Guangzhou High-tech Zone Science and Technology Holding Group


Founded on November 27, 1998, Guangzhou High-tech Zone Science and Technology Holding Group is a second-class wholly-owned subsidiary of GDD Financial Holdings Group, a wholly state-owned company established in Guangzhou Development Zone to accelerate the economic development in there. 


>>>>

About Jinhe Capital


Jinhe Capital is engaged in industrial investment, investment management consulting and other businesses, focusing on medical and other fields.

相关赛道 IVD
注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。

Mailman

医疗行业观察者

分享
动脉橙
以上数据来自动脉橙产业智库

我们以独创的在线数据库方式,为健康产业人士提供全方位和实时的市场资讯、行业数据和分析师见解。现已覆盖数字健康、医疗器械、生物医药等近500+细分赛道,涉及公司名单、招投标、投融资信息、头部企业动态等各类数据并持续更新。

点击 【申请试用】了解动脉橙产业智库更多内容。
精彩内容推荐

GensKey Receives a ¥100 Million Stragetic Financing from CPE

Chinagene Tech Secures ¥70 million in Series Pre-A Funding Round

Onechip Bioelectronics Snares ¥10M in Series B from MatrixPartners China

Biotechnology Company Matridx Completes ¥100M Pre-A Round of Financing

Mailman

共发表文章3245篇

最近内容
  • 知之甚少:调研885名投资人后,原来美国VC们这样做决策

    2023-03-20

  • 辉瑞想要收购Seagen只是开始,这才是2023年并购的两大趋势

    2023-03-05

  • 【融资】核药企业Ratio再融资2000万美元,和拜耳合作研究新前列腺癌放射性疗法

    2023-02-09

上一篇

MabPlex Closes ¥500M Series B Funding Round

2020-06-15
下一篇

Baisheng Biological Snags ¥10M in Angel Round

2020-06-15